PharmaTher Introduces PatchPrint(TM) With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches

Executive Summary

• PharmaTher Holdings Ltd. filed a provisional patent application (U.S. Patent Application No. 64/015,408) for “PatchPrint™,” an automated tabletop microneedle‑patch 3D printer that integrates demolding, packaging and multi‑product processing.
• The new platform is intended to support existing PharmaPatch™ programs (ketamine, psychedelics, GLP‑1, therapeutic peptides) and create on‑demand personalized patch solutions for pharmaceuticals, wellness, diagnostics, defense and humanitarian markets.
• PharmaTher has begun discussions with a medical‑focused 3D printer manufacturer to establish supply‑chain, engineering and go‑to‑market pathways for commercializing PatchPrint™ systems.

Key Details

• Patent filing: Provisional application titled “Automated Tabletop Microneedle Patch Printer with Integrated Demolding, Packaging, and Multi‑Product Cargo‑Adaptive Processing,” Application No. 64/015,408 filed with the USPTO.
• Platform capabilities: Compact tabletop printer that automates dispensing, vacuum loading, accelerated drying, demolding and packaging; supports a broad range of payloads (small molecules, proteins, peptides, biologics, dietary supplements).
• Target deployment sites: Pharmaceutical companies, hospitals, compounding pharmacies, remote/field settings for medical countermeasures and vaccines.
• Strategic purpose:
• Scale existing PharmaPatch™ pipelines (ketamine, psychedelic compounds, GLP‑1, therapeutic peptides).
• Enable partner‑facing development, manufacturing and deployment services for third‑party pharma/biotech firms, consumer brands and government agencies.
• Commercialization plan: Engaged with a medical‑focused 3D printer manufacturer to secure supply chain and engineering support; aims to launch PatchPrint™ systems for on‑demand production in hospitals, pharmacies and life‑science companies.
• Growth opportunities outlined: Therapeutics (peptides, metabolic disorders), consumer health/wellness (wound care, cosmeceuticals), diagnostics, vaccines, medical countermeasures, defense and humanitarian applications.
• Potential revenue streams: Platform licensing, contract manufacturing services, sales of PatchPrint™ hardware, co‑development agreements, branded patch products.

Notable Quotes

“This patent filing is an exciting step in PharmaTher's evolution into a microneedle patch platform company,” said Fabio Chianelli, CEO of PharmaTher.
“By combining our intellectual property, product innovation and partner‑driven execution, we aim to establish PharmaTher as a differentiated partner for companies seeking scalable, user‑friendly and on‑demand patch solutions.”